1026923-08-9

Basic information

• Product Name: [5-Benzyloxycarbonylamino-2-(4-formylamino-phenyl)-6-oxo-6H-pyrimidin-1-yl]-acetic acid
• CAS NO: 1026923-08-9
• Molecular Weight: 422.397
• Mol File: 1026923-08-9.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: [5-Benzyloxycarbonylamino-2-(4-formylamino-phenyl)-6-oxo-6H-pyrimidin-1-yl]-acetic acid(CAS DataBase Reference)
• NIST Chemistry Reference: [5-Benzyloxycarbonylamino-2-(4-formylamino-phenyl)-6-oxo-6H-pyrimidin-1-yl]-acetic acid(1026923-08-9)
• EPA Substance Registry System: [5-Benzyloxycarbonylamino-2-(4-formylamino-phenyl)-6-oxo-6H-pyrimidin-1-yl]-acetic acid(1026923-08-9)

Safety Data

• Hazardous Substances Data: 1026923-08-9(Hazardous Substances Data)

Upstream product

• 1026559-74-9 [1-(2,2-Dimethoxy-ethyl)-2-(4-formylamino-phenyl)-6-oxo-1,6-dihydro-pyrimidin-5-yl]-carbamic acid benzyl ester 
• 1026356-03-5 1-(2,2-Dimethoxy-ethyl)-2-(4-formylamino-phenyl)-6-oxo-1,6-dihydro-pyrimidine-5-carboxylic acid methyl ester 
• 1027421-58-4 1-(2,2-Dimethoxy-ethyl)-2-(4-formylamino-phenyl)-6-oxo-1,6-dihydro-pyrimidine-5-carboxylic acid 
• 6321-94-4 N-(4-cyanophenyl)formamide 
• 1025973-04-9 [2-(4-Formylamino-phenyl)-6-oxo-1-(2-oxo-ethyl)-1,6-dihydro-pyrimidin-5-yl]-carbamic acid benzyl ester 

Relevant articles and documents

Nonpeptidic inhibitors of human leukocyte elastase. 5. Design, synthesis, and X-ray crystallography of a series of orally active 5-aminopyrimidin-6- one-containing trifluoromethyl ketones

The effects of changes in substitution in a series of 5-amino-2- pyrimidin-6-ones on both in vitro activity and oral activity in an acute hemorrhage assay have been explored. These compounds contained either a trifluoromethyl ketone or a boronic acid moiety to bind covalently to the Ser-195 hydroxyl of human leukocyte elastase (HLE). Boronic acid-containing inhibitors were found to be more potent than the corresponding trifluoromethyl ketones in vitro but were less active upon oral administration. Compound 13b was found to offer the best combination of oral potency, duration of action, and enzyme selectivity and, as such, was selected for further biological testing. X-ray crystallography of a cocrystallized complex of compound 19m and porcine pancreatic elastase demonstrated that the inhibitor is bound to the enzyme in a manner similar to that found previously for a closely related series of pyridone-containing inhibitors of HLE.